Soluble receptor for advanced glycation end-products and progression of airway disease

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Iwamoto, Hiroshi ^a,b   Gao, Jing ^a   Pulkkinen, Ville ^a   Toljamo, Tuula ^c   Nieminen, Pentti ^d   Mazur, Witold ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b HIROSHIMA UNIVERSITY   (Japan)

^c LAPLAND CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SMOKING; BLOOD; COHORT ANALYSIS; FINLAND; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VITAL CAPACITY;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FINLAND; HMGB1 PROTEIN; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, IMMUNOLOGIC; REGRESSION ANALYSIS; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SMOKING; VITAL CAPACITY;

EID: 84899954220     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-68     Document Type: Article

References (27)

1. Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 2011, 36(12):625-632. 10.1016/j.tibs.2011.08.008, 22019011.
2. Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010, 2010:917108. 2817378, 20145712.
3. Ohlmeier S, Mazur W, Salmenkivi K, Myllarniemi M, Bergmann U, Kinnula VL. Proteomic studies on receptor for advanced glycation end product variants in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Proteomics Clin Appl 2010, 4(1):97-105. 10.1002/prca.200900128, 21137019.
4. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 2011, 37(3):516-522. 10.1183/09031936.00029310, 20595148.
5. Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM, Gibson PG, Wark PA. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 2012, 39(3):721-729. 10.1183/09031936.00022011, 21920897.
6. Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011, 12:37. 10.1186/1465-9921-12-37, 3072955, 21450080.
7. Iwamoto H, Gao J, Koskela J, Kinnula V, Kobayashi H, Laitinen T, Mazur W. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J 2014, 43(2):421-429. 10.1183/09031936.00024313, 23794464.
8. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agusti A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG, . Tesra; TESRA and ECLIPSE Investigators Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 188(8):948-957. 10.1164/rccm.201302-0247OC, 23947473, Tesra; TESRA and ECLIPSE Investigators.
9. Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H, Kourteva G, Bitter H, Pillai SG, Visvanathan S, Muller KC, Holz O, Magnussen H, Watz H, Fine JS. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One 2012, 7(6):e38629. 10.1371/journal.pone.0038629, 3373533, 22701684.
10. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008, 14(7-8):476-484. 2323334, 18431461.
11. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006, 17(3):189-201. 10.1016/j.cytogfr.2006.01.003, 16513409.
12. Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M, Dombret MC, Sims GP, Kolbeck R, Coyle AJ, Aubier M, Pretolani M. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181(9):917-927. 10.1164/rccm.200903-0340OC, 20133931.
13. Hou C, Zhao H, Liu L, Li W, Zhou X, Lv Y, Shen X, Liang Z, Cai S, Zou F. High mobility group protein B1 (HMGB1) in Asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol Med 2011, 17(7-8):807-815. 3146613, 21380479.
14. Boschetto P, Campo I, Stendardo M, Casimirri E, Tinelli C, Gorrini M, Ceconi C, Fucili A, Potena A, Papi A, Ballerin L, Fabbri LM, Luisetti M. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Invest 2013, 43(6):562-569. 10.1111/eci.12079, 23590548.
15. Ko HK, Hsu WH, Hsieh CC, Lien TC, Lee TS, Kou YR. High expression of high-mobility group box 1 in the blood and lungs is associated with the development of chronic obstructive pulmonary disease in smokers. Respirology 2014, 19(2):253-261.
16. Toljamo T, Kaukonen M, Nieminen P, Kinnula VL. Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study. Scand J Prim Health Care 2010, 28(1):41-46. 10.3109/02813431003630105, 3440614, 20331388.
17. Mazur W, Toljamo T, Ohlmeier S, Vuopala K, Nieminen P, Kobayashi H, Kinnula VL. Elevation of surfactant protein A in plasma and sputum in cigarette smokers. Eur Respir J 2011, 38(2):277-284. 10.1183/09031936.00110510, 21273386.
18. Viljanen AA, Halttunen PK, Kreus KE, Viljanen BC. Spirometric studies in non-smoking, healthy adults. Scand J Clin Lab Invest Suppl 1982, 159:5-20.
19. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013, 187(4):347-365. 10.1164/rccm.201204-0596PP, 22878278.
20. Han MK, Postma D, Mannino DM, Giardino ND, Buist S, Curtis JL, Martinez FJ. Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med 2007, 176(12):1179-1184. 10.1164/rccm.200704-553CC, 2720110, 17673696.
21. O'Donnell DE, Deesomchok A, Lam YM, Guenette JA, Amornputtisathaporn N, Forkert L, Webb KA. Effects of BMI on static lung volumes in patients with airway obstruction. Chest 2011, 140(2):461-468. 10.1378/chest.10-2582, 21310838.
22. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000, 161(2 Pt 1):381-390.
23. Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber EP. Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 2006, 323(3):475-488. 10.1007/s00441-005-0069-0, 16315007.
24. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4(9):1025-1031. 10.1038/2012, 9734395.
25. Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, Fattman CL, Ramsgaard L, Richards TJ, Loutaev I, Nawroth PP, Kasper M, Bierhaus A, Oury TD. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008, 172(3):583-591. 10.2353/ajpath.2008.070569, 2258251, 18245812.
26. Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A, Fauerbach PN, Lomas DA, Macnee W, Mayer RJ, Miller BE, Muller NL, Rennard SI, Silverman EK, Tal-Singer R, Wouters EF, Vestbo J. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med 2013, 1(2):129-136. 10.1016/S2213-2600(13)70006-7, 24429093.
27. Shang GH, Jia CQ, Tian H, Xiao W, Li Y, Wang AH, Dong L, Lin DJ. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 2009, 103(12):1949-1953. 10.1016/j.rmed.2009.05.019, 19535236.